SEGMENT REPORTING (Tables)

3 Months Ended

Mar. 31, 2016

Segment Reporting [Abstract]

Reconciliation of other significant reconciling items from segments to consolidated

Summarized financial information concerning the Company's reportable segments is shown in the following table (in thousands):

Three Months Ended March 31, 2015	Core Companion Animal Health		Other Vaccines, Pharmaceuticals and Products		Total
Total revenue	$	19,572	$	3,322	$	22,894
Operating Income	535		486		1,021
Income before income taxes	410		474		884
Capital expenditures	307		298		605
Depreciation and amortization	830		176		1,006

Three Months Ended March 31, 2016	Core Companion Animal Health		Other Vaccines, Pharmaceuticals and Products		Total
Total revenue	$	23,434	$	3,712	$	27,146
Operating Income	1,758		212		1,970
Income before income taxes	1,808		295		2,103
Capital expenditures	397		508		905
Depreciation and amortization	897		199		1,096

Schedule of revenue from external customers and long-lived assets, by geographical areas

Total revenue by principal geographic area was as follows (in thousands):

	Three Months Ended March 31,
	2015		2016
United States	$	22,279	$	26,480
Europe	615		666
Total	$	22,894	$	27,146

Asset information by reportable segment as of December 31, 2015 is as follows (in thousands):

	Core Companion Animal Health		Other Vaccines, Pharmaceuticals and Products		Total
Total assets	$	92,567	$	17,152	$	109,719
Net assets	48,175		15,353		63,528

Asset information by reportable segment as of March 31, 2016 is as follows (in thousands):

	Core Companion Animal Health		Other Vaccines, Pharmaceuticals and Products		Total
Total assets	$	93,330	$	16,762	$	110,092
Net assets	57,152		8,353		65,505

Total assets by principal geographic areas were as follows (in thousands):

	December 31,		March 31,
	2015		2016
United States	$	106,780	$	106,980
Europe	2,939		3,112
Total	$	109,719	$	110,092